Nintedanib: A New Treatment for Idiopathic Pulmonary Fibrosis
Created 3 months ago by marykudro

Nintedanib, an intracellular inhibitor of tyrosine kinases approved as a treatment for patients with idiopathic pulmonary fibrosis (IPF) by regulatory authorities in the USA and Europe. The nintedanib 150 mg price in India is absolutely reasonable. Nintedanib comes as a capsule to administer orally. It is usually administered with food every 12 hours (twice daily). Take capsules of nintedanib at around the same times every day. The side effects most frequently linked with the therapy are gastrointestinal in nature, particularly diarrhea. In maximum patients, such adverse events can be managed through dose reduction, treatment interruption, and symptomatic therapy.